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The human Cranio Facial Development Protein 1 (Cfdp1) gene maps to chromosome 16q22.2-q22.3 and 
encodes the CFDP1 protein, which belongs to the evolutionarily conserved Bucentaur (BCNT) family. 
Craniofacial malformations are developmental disorders of particular biomedical and clinical interest, 
because they represent the main cause of infant mortality and disability in humans, thus it is important 
to understand the cellular functions and mechanism of action of the CFDP1 protein. We have carried 
out a multi-disciplinary study, combining cell biology, reverse genetics and biochemistry, to provide the 
first in vivo characterization of CFDP1 protein functions in human cells. We show that CFDP1 binds to 
chromatin and interacts with subunits of the SRCAP chromatin remodeling complex. An RNAi-mediated 
depletion of CFDP1 in HeLa cells affects chromosome organization, SMC2 condensin recruitment and 
cell cycle progression. Our findings provide new insight into the chromatin functions and mechanisms of 
the CFDP1 protein and contribute to our understanding of the link between epigenetic regulation and 
the onset of human complex developmental disorders.
Chromatin organization is highly dynamic and subject to many epigenetic changes, mediated by histone modify-
ing enzymes and ATP-dependent chromatin remodeling complexes1. These complexes are multi-protein molec-
ular devices able to slide or displace nucleosomes, thus making DNA more accessible to specific binding proteins 
that control essential cellular processes, such as transcription, replication and DNA repair.
Over the last decade, growing evidence has shown that mutations in genes which encode the epigenetic reg-
ulators controlling chromatin configuration can promote cancer and human developmental disorders2–9. An 
emblematic case of these “chromatin diseases” is the developmental genetic syndrome called CHARGE10, which 
is caused by mutations in the gene encoding a member of the CHD family of ATP-dependent chromatin remod-
eling enzymes4,11. The identification of new candidate genes and proteins will challenge us to expand our under-
standing of how epigenetic alterations of chromatin structure can perturb development and trigger the onset of 
human diseases, and will have a significant impact on applied research.
One possible candidate in human developmental diseases is the Cranio Facial Development Protein 1 
gene (Cfdp1). Cfdp1 is 139,815 bp long with 7 exons and 6 introns and maps to chromosome 16 in the band 
16q22.2-q22.3, where it is proximally and distally flanked by Bcar1 and Tmem170A genes, respectively12–15. Cfdp1 
expression has been detected in a wide range of human tissues, including cancer tissues. It encodes a protein of 
299 amino acids, called CFDP1, belonging to the evolutionarily conserved family of Bucentaur (BCNT) pro-
teins12–15. The CFDP1 protein is characterized by an 82-amino acid region located at the C-terminus, called the 
BCNT-C domain, which is highly conserved among almost all eukaryotes, while the N-terminal region is more 
divergent12–14.
1Istituto Pasteur Italia-Fondazione Cenci Bolognetti and Dipartimento di Biologia e Biotecnologie “Charles Darwin”, 
Sapienza Università di Roma, Italy. 2Dipartimento di Biologia e Biotecnologie “Charles Darwin” Sapienza Università 
di Roma, Roma, Italy. 3CNIO, Madrid, Spain. Correspondence and requests for materials should be addressed to G.M. 
(email: giovanni.messina@uniroma1.it) or P.D. (email: patrizio.dimitri@uniroma1.it)
Received: 30 September 2016
accepted: 20 February 2017
Published: 03 April 2017
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7:45022 | DOI: 10.1038/srep45022
The functions of Cfdp1 orthologs have been investigated in different species12,13. In particular, the observation 
that mouse Cfdp1 is expressed during tooth development suggested an involvement of this gene in craniofacial 
development15,16. Further evidence linked the CFDP1 proteins to craniofacial development and osteogenesis in 
vertebrates17–20, although specific syndromes caused by mutations of Cfdp1 have not yet been identified.
An integrative global proteomic study provided evidence suggesting that the CFDP1 protein interacts with 
members of the SNF2-related CBP activator protein (SRCAP) chromatin remodeling complex21 which catalyzes 
an ATP-dependent exchange of canonical histone H2A for variant H2A.Z in humans22. Intriguingly, truncating 
mutations of the Srcap gene cause the rare Floating Harbor syndrome that, among other defects, includes 
craniofacial abnormalities9.
Drosophila YETI and yeast SWC5, two orthologs of CFDP1, were found to be subunits of the d-Tip60 and 
Swr1 chromatin remodeling complexes, respectively23,24. Both d-Tip60 and Swr1 complexes share a dozen subu-
nits with the SRCAP complex and are functionally and evolutionarily related to it, in that they also govern variant 
H2A loading onto chromatin1,23,25–28.
More recently, it has been shown that the CFDP1 protein expressed in wild-type Drosophila melanogaster is 
able to bind salivary gland polytene chromosomes, strongly affecting chromatin organization and H2Av depo-
sition in a dominant-negative fashion29. In addition to its possible role in chromatin remodeling, CFDP1 may 
also have autonomous functions in transcriptional regulation, as suggested by its interactions with SMAD3 and 
Ewings Sarcoma (EWS) proteins, which are involved in the modulation of transcription30.
Thus far, studies on the in vivo function(s) of CFDP1 in human cells are missing.
In the present work, by combining cell biology with reverse genetics and biochemical approaches, we per-
formed a functional analysis of the role played by the CFDP1 protein in human cells. We used Western blot-
ting to detect two endogenous CFDP1 isoforms of 50 and 35 kDa in HeLa, U2OS and MRC5 cell lines. 
Immunofluorescence microscopy (IFM) and chromatin fractionation assays, together with the expression of 
intact or truncated Flag-CFDP1 proteins, suggest that the 50 kDa isoform is a chromatin-binding protein that 
interacts with the SRCAP chromatin remodeling complex. In addition, the depletion of endogenous CFDP1 in 
HeLa cells drastically affects higher-order chromatin organization and cell cycle progression.
Results
Nuclear localization and chromatin association of CFDP1 in human cell lines. We initially per-
formed Western blotting assays on total protein extracts from HeLa, U2OS and MRC5 cell lines, using a mouse 
monoclonal antibody to CFDP1 (see Materials and Methods). The results showed the presence of two sharp 
bands of about 50 kDa and 35 kDa in all three cell lines (Fig. 1A). The Cfdp1 gene is predicted to undergo alter-
native splicing, giving rise to two mRNAs which differ for the presence or absence of the last exon (http://www.
uniprot.org/blast/?about= Q9UEE9-2). It is conceivable that the 50 kDa and 35 kDa bands represent the CFDP1 
isoforms 1 and 2, respectively, the shorter isoform lacking the last 82 amino acids which correspond to the evolu-
tionary conserved BCNT domain.
Next, we used immunofluorescence microscopy (IFM) with the same monoclonal antibody to visualize the 
cellular localization of the endogenous CFDP1. As shown in Fig. 1B, CFDP1 is present in the nucleus of HeLa 
cells in interphase but is not seen on mitotic chromosomes. The staining of interphase nuclei was confirmed by 
additional IFM experiments performed in HeLa, U2OS and MRC5 cell lines using a rabbit polyclonal antibody to 
CFDP1 (Fig. 1C,D,E; see Materials and Methods). To validate the specificity of the antibodies to CFDP1, Western 
blotting and IFM experiments were performed after RNAi-mediated depletion of CFDP1 in HeLa cells. As shown 
in Fig. 1F,G,H, the amount of CFDP1 was lower in RNAi-treated cells compared to mock-treated cells.
The absence of anti-CFDP1 staining on chromosomes (Fig. 1B) may suggests that CFDP1 is not bound to 
chromatin in mitosis, similarly to what has been found for HMG-14/-17 proteins31. Alternatively, CFDP1 could 
also be present in mitotic chromatin, but less accessible to the antibody. To discriminate between these two 
hypotheses, we performed a fractionation assay on HeLa cells synchronized in interphase (G1/S) or metaphase. 
As shown in Fig. 2A, the 50kDa band of CFDP1 is found at comparable amounts in the chromatin-bound fraction 
(P3) of both interphase and metaphase cell extracts. In summary, CFDP1 is expressed in human cells of different 
origins, probably as two differently spliced variants and is bound to chromatin in both interphase and metaphase, 
although is not visualized on chromosomes by immunostaining.
Chromatin association of CFDP1 requires both N- and C-terminal regions. To further validate the 
nuclear localization and chromatin binding ability of CFDP1, as is the case for the Drosophila melanogaster ort-
holog YETI24, we expressed flag-tagged CFDP1 from a full length cDNA and two truncated cDNAs that carried 
either the N-terminal or the C-terminal portion of the gene, in HeLa cells (see Materials and Methods). Worth 
noting, the Flag-CFDP1-Nt variant exactly matches the putative isoform 2 of CFDP1, in that it carries the first 217 
amino acids and lacks the C-terminal BCNT domain (Fig. 2B).
IFM showed that Flag-CFDP1, Flag-CFDP1-Nt and Flag-CFDP1-Ct are all able to enter the cell nuclei 
(Fig. 3C,D,E). A fractionation assay, however, showed all the three forms present in the soluble fractions, while 
only Flag-CFDP1 is detectable in the chromatin-bound fractions (Fig. 2F). It appears that both Flag-CFDP1-Nt 
and Flag-CFDP1-Ct truncated forms are defective for the chromatin binding activity. We must conclude that 
two different regions of CFDP1, one included in Flag-CFDP1-Nt and the other in Flag-CFDP1-Ct, are present 
simultaneously for chromatin binding. In addition, these results, together with the results obtained in synchro-
nized HeLa cells (Fig. 2A), strongly suggest that the chromatin-binding activity is specific to the 50 kDa isoform 
of CFDP1, while the 35 kDa isoform may have different functions.
Depletion of CFDP1 in HeLa cells affects chromosome organization and condensin recruitment 
in mitosis. To investigate the function of CFDP1 protein in human cells, we performed a cytological analysis 
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Figure 1. Expression and localization of CFDP1 protein in human cells (A) Western blotting of protein extracts 
from HeLa, U2OS and MRC5 cells with a mouse monoclonal antibody against human CFDP1 (bottom) and 
ISWI (hSNF2) as loading control (top). The intensity of the 35 kDa band differs between human cells lines 
tested, being lower in U2OS and MRC5 cells compared to HeLa; this observation suggests that the synthesis of 
the 35 kDa band (CFDP1 isoform 2) is subjected to regulatory controls. Both 50 kDa and 35 kDa bands are also 
recognized by a rabbit polyclonal antibody to CFDP1 (see G). (B) Fixed HeLa cells were stained with the mouse 
monoclonal antibody to CFDP1 (red) and counterstained with DAPI (blue). The CFDP1 staining is clearly 
present in the interphase nuclei, while no significant staining was detected on mitotic chromosomes (pointed 
by arrows). (C,D,E) Human cell lines were also incubated with a rabbit polyclonal antibodies to human CFDP1 
and with commercial antibodies to α -tubulin. From left to right panels: DAPI (blue), α -tubulin (green), CFDP1 
(red) and merge in: (C) HeLa, (D) U2OS and (E) MRC5 cells. A significant fluorescent staining of interphase 
nuclei was observed in all the three lines. (F) and (G) Western blotting with mouse monoclonal and rabbit 
polyclonal antibodies to CFDP1, respectively; it appears that in RNAi-treated cells (RNAi lane) the intensity 
of both CFDP1 bands is strongly reduced compared to the mock-treated control cells (mock 100% lane); ISWI 
(hSNF2) was used as control (top). (H) The CFDP1 nuclear staining with monoclonal antibodies shows about 
70% decreased in RNAi-treated HeLa cells compared to the mock.
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of fixed HeLa cell preparations after RNAi-mediated knock-down of Cfdp1 (see Materials and Methods). The 
efficiency of CFDP1 protein depletion was monitored by Western blotting, as previously shown in Fig. 1F,G. 
Metaphase chromosomes from CFDP1-depleted cells displayed aberrant morphology and condensation defects 
when compared to mock-treated cells (Fig. 3A–C). In a total of 115 scored metaphase chromosome spreads, 
45% of abnormally condensed figures were seen in Cfdp1-siRNA treated cells, while only 3% of such metaphases 
were found in the mock-treated controls. Thus, it appears that CFDP1 activity is required for the maintenance 
of proper higher-order chromatin organization in human cells. This behavior strongly resembles that of the 
Drosophila YETI protein24. In addition, the count of mitotic figures showed that the mitotic index in CFDP1 
depleted cells is decreased about 75% compared to controls (Fig. 3P), indicating that the loss of CFDP1 can also 
affect cell cycle progression.
Given that the condensin complexes play a key role in chromosome condensation, we also studied the local-
ization of SMC2, a subunit of the condensin I and II complexes32 in CFDP1-depleted HeLa cells. The results of 
this analysis are shown in Fig. 3D,E,H,I. In about 80% of metaphase cells (634 in total) a significant loss of chro-
mosomal SMC2 was detected (Fig. 3Q). We also observed a high proportion (30%) of telophases with chromatin 
bridges (Fig. 3F,G,L,M,N,O,R). This abnormality may be the consequence of chromosome stickiness due to con-
densation defects. Together, these results strongly support a role for CFDP1 in chromatin organization.
Figure 2. Chromatin association of CFDP1 in HeLa cells (A) Western blot analysis of fractionated HeLa 
cells after synchronization in interphase (G1/S) or metaphase (see material and methods). As metaphase 
synchronization controls, the histone 3 phosphorylated in serine 10 (H3p) and SMC2 condensin have been 
used. H3p is a DNA condensation marker which is found only in mitotic chromatin, while SMC2 increases in 
condensed chromatin. As expected, H3p is specifically present in the chromatin-bound fraction (P3) of HeLa 
cells synchronized in metaphase. In the same fraction, the amount of SMC2 is higher compared to that of cells 
synchronized in G1/S. CFDP1 is detected at comparable amount in the chromatin-bound fractions (P3) of both 
interphase and metaphase, similar to histone H3. (B) Schematic representation of Flag-CFDP1 tagged proteins; 
Flag-CFDP1 full-length, isoform 1(aa 1-299); Flag-CFDP1-Nt, isoform 2 (1–217) and Flag-CFDP1-Ct, BCNT 
domain (218–299). (C) From left to right panels: DAPI (blue), α -tubulin (green), Flag-CFDP1 (red) and merge. 
(D) From left to right panels: DAPI (blue), α -tubulin (green), Flag-CFDP1-Nt (red) and merge. (E) From left 
to right panels: DAPI (blue), α -tubulin (green), Flag-CFDP1-Ct (red) and merge. (F) Western blot analysis 
of fractionated HeLa cells after transfection with Flag-CFDP1 or truncated variants. Flag-CFDP1 is detected 
in soluble (S2 and S3) and chromatin-bound (P3) fractions, while Flag-CFDP1-Nt and Flag-CFDP1-Ct are 
found only in the soluble fractions (S2 and S3). MEK2 and H3 are specific controls for soluble and chromatin 
fractions, respectively. Anti-MEK2, mitogen-activated protein (MAP)/ERK kinase 2, was used as cytoplasmic 
contamination control in P3 fraction; anti-histone H3 was used to monitor chromatin contamination in 
soluble fraction. WCE = whole cell extract; S2 = cytoplasmic soluble fraction; S3 = nuclear soluble fraction, 
P3 = chromatin-bound fraction.
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Expression of Flag-YETI in HeLa cells mimics CFDP1 depletion. Our previous results suggest that when 
CFDP1 is expressed in wild-type fruit flies, it can physically interact with YETI to form inactive heterodimers; this 
would result in an overall depletion of functional YETI with a consequent disruption of chromatin organization and 
individual viability29. To test whether YETI overexpression may affect cell behavior in human cells, we transiently 
transfected HeLa cells with Flag-Yeti and V5-Cfdp1 cDNA constructs. The IF staining showed that V5-CFDP1 and 
Flag-YETI are able to enter the nuclei (Fig. 4A–C). Moreover, in a fractionation assay both Flag-YETI and V5-CFDP1 
Figure 3. Mitotic defects after RNAi depletion of CFDP1 in HeLa cells (A) Metaphase chromosomes from 
mock-treated HeLa cells; (B) and (C) Clearly aberrant metaphase chromosomes that fail to undergo proper 
condensation found in RNAi treated HeLa cells; condensing chromatin appeared fuzzy, loose and largely 
disorganized. Hela cells were treated with Colcemid to enrich for metaphase chromosomes. (D) and (E) DAPI 
and SMC2 condensin sequential staining of mock treated cells; the SMC2 staining decorates the chromatid axes 
(H) and (I) DAPI and SMC2 condensin sequential staining of CFDP1 depleted cells; the SMC2 staining is very 
faint. (F) and (L) DAPI and α -tubulin staining of telophases in mock-treated cells; (N) Merge; (G) and (M) 
DAPI and α -tubulin staining of telophases in CFDP1 depleted cells; (O) Merges. The arrow in (G) points an 
example of chromatin bridge. (P) Quantification of the mitotic index of CFDP1 depleted cells compared to the 
mock. The mitotic index is expressed as the percentage of the total population of cells in mitosis (n = 1000). Cell 
cycle stages were determined by scoring all mitotic cells by IF for α -tubulin and chromosome staining; black 
and white histograms represent % of cells in mitosis in mock and CFDP1-depleted cells, respectively.  
(Q) Quantification of loss of chromosomal SMC2 in CFDP1-depleted cells compared to the mock; black 
and white histograms represent % of cells with normal or aberrant distribution of SMC2 respectively. (R) 
Quantification of telophases showing chromatin bridges in CFDP1 depleted cells compared to the mock. About 
30% of telophases show the occurrence of chromatin bridges. Black and white histograms represent % of normal 
and aberrant telophases in mock and CFDP1-depleted cells, respectively.
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were found in the chromatin-bound fraction, as well as in the soluble fraction (Fig. 4D). As shown in Fig. 4E, HeLa 
cells overexpressing Flag-YETI exhibit a significant decrease in mitotic index (about 50%), although the effect is not 
as strong as in CFDP1 depleted cells. By contrast, the overexpression of the V5-CFDP1 fusion protein did not affect 
mitotic index. In addition, in HeLa cells overexpressing both Flag-Yeti and V5-Cfdp1 constructs, the V5-CFDP1 fusion 
protein is not able to rescue the mitotic index decrease (Fig. 4E). To test whether CFDP1 and YETI interact in vivo, 
immunoprecipitation assays were performed in HeLa cells transfected with both V5-Cfdp1 and Flag-Yeti constructs. 
As shown in Fig. 4F, FLAG-YETI fusion protein was detected in the IP sample immunoprecipitated with V5 antibody, 
but not in IgG negative control. Together, these findings suggest that CFDP1 and YETI can physically interact in vivo, 
giving rise to inactive heterodimers that can affect cell viability.
Co-IP assays in HeLa cells. As discussed in the introduction, a global proteomic study provided evidence that 
the CFDP1 protein interacts with members of the SNF2-related CBP activator protein (SRCAP) chromatin remodeling 
complex21. However, thus far these data have been not validated in vivo. To test whether CFDP1 interacts in vivo with 
members of the SRCAP complex, we performed a series of co-IP assays. HeLa cells were transfected with 3 different 
expression vectors containing different tagged proteins: CFDP1 tagged with V5 (V5-CFDP1), H2A.Z tagged with HA 
(HA-H2A.Z) and Arp6 tagged with Myc (Myc-Arp6). In parallel, HeLa cells were also transfected with two expression 
vectors containing CFDP1 tagged with V5 (V5-CFDP1) and SRCAP tagged with HA (HA-SRCAP). Cell extracts were 
immunoprecipitated with anti-V5 antibodies and then analyzed by Western blotting using antibodies against anti-Myc, 
HA and other known components of the SRCAP complex. As a negative control, we used HeLa cell extracts immuno-
precipitated with Ms IgG.
As shown in Fig. 5, Myc-Arp6, P18Hamlet and H2A were detected in V5-CFDP1 immunoprecipitates, but were 
absent in the Ms IgG control. By contrast, HA-H2A.Z and HA-SRCAP were not detected in the IP. These results 
suggest that CFDP1 interacts with Arp6 and P18Hamlet which are known members of the SRCAP complex.
Independent experimental evidence has shown that YETI interacts with HP1α in Drosophila melanogaster24,33. 
Given that, we also analyzed V5-CFDP1 immunoprecipitates using antibodies against HP1α . A reproducible HP1α 
band, although of weak intensity, was apparent in the IP sample and absent in the control (Fig. 5), suggesting that the 
interaction between BCNT proteins and HP1α is maintained during evolution.
Figure 4. Drosophila YETI impairs CFPD1 function in HeLa cells (A) DAPI staining of HeLa cells expressing 
Flag-YETI (left panel) or V5-CFDP1 (right panel); (B) Nuclear localization of V5-CFDP1 (left panel) and Flag-
YETI (right panel) proteins. (C) Merges; (D) Western blot analysis of fractionated HeLa cells after V5-Cfdp1/
Flag-Yeti transfection. WCE, whole cell extract; S2, cytoplasmic soluble fraction; P3, chromatin-bound fraction. 
(E) Analysis of mitotic index of HeLa cells. HeLa cells overexpressing V5-CFDP1 fusion protein slightly 
increases mitotic index, compared to the mock-transfected control. RNAi-mediated depletion of CFDP1 
produces about 75% reduction of mitotic index; FLAG-YETI overexpression causes a 60% reduction of mitotic 
index; (F) For IP assays, protein lysate was prepared from HeLa expressing V5-CFDP1 and FLAG-YETI fusion 
proteins and immunoprecipitated using a mouse anti-V5 antibody. A FLAG-YETI band is detected in the V5-
immunoprecipitate, but not in Ms IgG negative control.
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Discussion
CFDP1 is required for chromatin organization in human cells. We have carried out the first in vivo 
functional characterization of the Cfdp1 gene and its encoded protein in human cells. Two different isoforms of 
the protein can be detected in HeLa, U2OS and MRC5 cell lines (Fig. 1A), which most likely result from alter-
native splicing. Both bands are the result of Cfdp1 expression, since their intensity strongly decreased following 
RNAi-mediated depletion of this gene (Fig. 1F,G).
Using IFM and chromatin fractionation we determined that CFDP1 has a nuclear localization and 
is found in the chromatin fraction in both interphase and metaphase (Figs 1 and 2). We also found that the 
chromatin-binding function of CFDP1 requires both its N- and C- terminal regions (Fig. 2). The N-terminal frag-
ment used in our experiments lacks the last 82 amino acids as does the 35 kDa isoform. This region corresponds 
to the evolutionarily conserved BCNT-domain that was found to be crucial for the chromatin-binding activity of 
YETI in D. melanogaster24. We speculate that the 50 kDa isoform of CFDP1 is the one that participates in chroma-
tin organization, while the 35 kDa isoform may have a different and still undetected function.
The results of co-IP assays (Fig. 5) indicated that in HeLa cells CFDP1 interacts with members of the SRCAP 
chromatin remodeling complex that exchanges H2A and H2A.Z histones (22). We also found an interaction with 
endogenous H2A, but not with HA-H2A.Z (Fig. 5). This finding suggests that CFDP1, by interacting with H2A, 
may play a role in an H2A-H2B eviction reaction, rather than in H2A.Z-H2B deposition.
In the light of these results, it is conceivable that CFDP1 bounds the chromatin through interaction with 
members of the SRCAP complex (Fig. 5) and that the N- and C- terminally truncated variants are unable to 
enter the complex. However, it cannot be completely ruled out that CFDP1 may also have an autonomous 
chromatin-binding activity independent of its interaction with the SRCAP complex.
RNAi-mediated depletion of CFDP1 led to mitotic chromosomes with aberrant morphology and condensa-
tion defects as well as chromosome segregation defects such as chromatin bridges (Fig. 3). These defects recall 
those exhibited by Yeti null alleles in Drosophila melanogaster24,34. Interestingly, the amount of SMC2 condensin, 
a major player in chromosome condensation that localizes to the axes of metaphase chromosomes, was strongly 
reduced in a high percentage of CFDP1-depleted cells (Fig. 3D,L,M,E). This could be a secondary consequence 
of drastic chromatin perturbations triggered by CFDP1 depletion. Alternatively, CFDP1 may play a direct role in 
the recruitment of condensin.
A recent study in fission yeast suggests that nucleosome eviction promotes condensin loading in mitosis35. This 
is interesting in view of the interaction we detected between CFDP1 and members of the SRCAP complex. In fact, 
both H2A and H2A.Z histones have also been proposed to be involved in condensin binding to chromatin36,37.
Moreover, the co-IP assays indicate that CFDP1 interacts with HP1α , in the same way that Drosophila YETI 
interacts with HP1a24,33. This finding suggests that BCNT proteins may be evolutionarily conserved mediators 
involved in the targeting of HP1 to chromatin remodeling regions.
We also found that Drosophila Flag-YETI expressed in HeLa cells enters the cell nucleus (Fig. 4A–C), binds 
to chromatin (Fig. 4D) and produces a strong decrease in the mitotic index (Fig. 4E), with an impairment of cell 
cycle progression. This could be due to the in vivo formation of inactive YETI-CFDP1 heterodimers (Fig. 4F), a 
result that corroborates our previous in vitro findings29.
CFDP1 and craniofacial development. Craniofacial malformations are developmental disorders of cru-
cial biomedical and clinical interest, since they represent the main cause of infant mortality and disability in 
humans. Together with cognitive defects and growth abnormalities, craniofacial malformations are common 
symptoms of epigenetic diseases6 and most known candidate genes are transcription factors and chromatin 
regulators38–40.
Figure 5. CFDP1 interacts with subunits of the SRCAP complex Total protein extracts from HeLa cells 
expressing V5-CFDP1, Myc-Arp6 and HA-H2A.Z or V5-CFDP1 and HA-SRCAP vectors were subjected 
to immunoprecipitation with the anti-V5 antibody. Input protein extracts (IN), flow-through (FT) and 
V5 immunoprecipitates (IP) were separated by SDS–PAGE and transferred onto a nitrocellulose membrane. 
Western blots were probed with α -V5, α -Myc, α -P18Hamlet, α -H2A, α -HP1α and α -ISWI antibodies. Myc-
Arp6, P18Hamlet, H2A and HP1α are present in the V5-CFDP1 immunoprecipitates, while they are absent 
from the immunoprecipitates of Ms IgG control. The HP1α present in V5 immunoprecipitates, although of 
weak intensity, has been detected in two independent experiments. HA-SRCAP and HA-H2A.Z has not been 
detected.
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Among craniofacial diseases, autosomal recessive primary microcephaly (MCPH) is a rare disorder charac-
terized by a reduction in brain size and head circumference at birth and mild to severe mental retardation. Thus 
far, mutations in 12 genes have been found in patients with MCPH; these genes affect cell cycle regulation and 
DNA repair41,42. Intriguingly, the MCPH1 gene encoding microcephalin38 shows some aspects in common with 
Cfdp1. Microcephalin was found to regulate one of the two condensin complexes present in the cell, condensin 
II43. Similar to cells lacking CFDP1, MCPH1-depleted cells display aberrant chromosome condensation44. It is 
unclear whether this is the major pathological mechanism in patients with MCPH1 mutations. Additional func-
tions of MCPH1 during chromosome shaping and dynamics may be influenced45. Similarly, depletion of CFDP1 
may affect other processes in addition to mitosis. Given its interaction with the SRCAP chromatin remodeler, 
the function of CFDP1 may affect both higher-order chromatin organization throughout the cell cycle and gene 
regulation. In any case, in view of the similarities with MCPH1, it would be interesting to include Cfdp1 gene in 
the sequencing panels for microcephaly and related human disorders.
In conclusion, our findings provide new insight into the functions and mechanisms of the CFDP1 protein and con-
tribute to our understanding of the link between epigenetic regulation and the onset of human craniofacial disorders.
Methods
Cytology and immunostaining. To analyze chromosome condensation, HeLa cells were treated at 37 °C 
for 2 h with 0,1 μ g/mL colcemid, harvested by trypsinization and treated with hypotonic buffer (0,075 M KCl) for 
10 min at room temperature. Cells were fixed with freshly made Fix solution (3:1 methyl alcohol:glacial acetic 
acid) at − 20 °C. Then, chromosome preparations were made by air-drying method. For IF staining, HeLa cells 
were seeded on glass coverslips and 24 h later they were fixed for 15′ at room temperature (RT) in 2% formal-
dehyde in PBS. Cells were treated with hypotonic solution (75 mM KCl) for 30′ at RT before fixation. After per-
meabilization in 0.2% Triton X-100 solution and washing in PBS, the cells were incubated in 3% bovine serum 
albumin (BSA) for 1 h and, subsequently, with primary antibodies for 2 h at RT. After several washes in PBS, the 
cells were incubated with secondary antibodies for 1 h at RT. After washing in PBS, the coverslips were mounted 
onto slides with anti-FADE solution containing the anti-bleaching agent DABCO (Sigma-Aldrich). Preparations 
were analyzed using a computer-controlled Nikon Eclipse 50i epifluorescence microscope equipped with a CCD 
camera. CFDP1 fluorescence intensity was assessed using the ImageJ software (http://rsbweb.nih.gov/ij/). About 
400 nuclei were scored in three independent experiments. The primary antibodies were: mouse monoclonal 
anti-CFDP1 (1:100; Sigma-Aldrich); rabbit polyclonal anti-CFDP1 (1:200; Thermo Scientific); rabbit polyclonal 
anti-hSMC246; and rabbit anti-beta Tubulin (1:4000, Loading Control, Abcam). The secondary antibodies were: 
Donkey anti-rabbit IgG-CFL 555 (Santa Cruz Biotechnology; 1:200); and goat anti-mouse IgG-CFL 488 (Santa 
Cruz Biotechnology; 1:200).
CFDP1 constructs. To make Flag-CFDP1 constructs, sequences corresponding to full length (Flag-CFDP1), 
N-terminal (Flag-CFDP1-Nt) and C-terminal/BCNT (Flag-CFDP1-Ct) of CFDP1 cDNA were cloned into the 
pENTR/D-TOPO (Invitrogen) and subcloned into pIRESpuro3-MycFlag/GATCassette Gateway destination 
vector. V5-CFDP1 and Flag-YETI plasmid are described in our previous papers24,29. The constructs pCS2-
5xMyc-Arp6, pcDNA3-HA-H2A.Z and pcDNA3-HA-SRCAP were described in ref. 47. For a description of the 
CFDP1 constructs, see Fig. S1.
Cell Cultures and RNAi treatments. HeLa cells, purchased from ATTC company, were cultured in 
6-well plates in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS and a Penicillin/
Streptomycin solution (Gibco, 15140122). Transfection was performed with 1 μ g of CFDP1 esiRNA using 
Dharmafect (Thermo Scientific) according to the manufacturer’s protocol. Endoribonuclease-prepared siRNA 
(esiRNA) that targets CFDP1 was purchased from Sigma-Aldrich. Two days after transfection cells were har-
vested for cytological and immunoblotting analysis.
Cell cycle Synchronization. For cell cycle-dependent chromatin binding experiments, HeLa cells were syn-
chronized in interphase (G1/S boundary) or metaphase using thymidine or thymidine/nocodazole blocks, respec-
tively. Briefly, for G1/S boundary synchronization, cells were treated with 2 mM thymidine (Sigma, T9250) for 19 h, 
washed with PBS, harvested by centrifugation and frozen in liquid nitrogen. For metaphase synchronization, after 
thymidine treatment, HeLa cells were released from G1/S block in fresh media for 5 h, incubated with 40 nM noco-
dazole (Sigma, M1403) for 16 h and then harvested by mitotic shake-off. Mitotic cells were washed three times with 
PBS and released in fresh medium for 30′ before harvesting and freezing in liquid nitrogen. Interphase and meta-
phase cell samples were prepared by resuspending cells in Buffer A for subsequent chromatin fractionation assay.
Chromatin Fractionation Assay. HeLa cells (2 × 107) were resuspended in 1 mL of Buffer A (10 mM 
HEPES at pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10% glycerol, 1 mM dithiothreitol [DTT], 1 mM 
NaVO4, 5 mM β -glycero-phosphate, 0.1 mM phenyl methane sulphonyl fluoride [PMSF], 0.5 mM NaF, protease 
inhibitor cocktail [Roche]). Triton X-100 was added at 0.1% and cells were incubated for 5′ on ice. After centrif-
ugation (4000 rpm for 5′ at 4 °C), the nuclei enriched pellet was resuspended in 1 mL of Buffer B (3 mM EDTA, 
0.2 mM EGTA, 1 mM DTT, 0.1 mM PMSF, protease inhibitors) and incubated for 5′ on ice. All the fractioned 
samples were load in a polyacrylamide gel and transferred onto PVDF membrane for Western blot analysis.
Immunoprecipitations. HeLa cells were transfected with 2 μ g of V5-Cfdp1 and Myc-Arp6 or HA-H2A.Z 
expression vectors by using Lipofectamine 3000 reagent according to the manufacture’s protocol, and 48 h later, 
they were lysated in IP buffer (50 mM Tris–HCl pH 7.5, 150 mM NaCl, 1% NP-40, 5 mM EGTA, 5 mM EDTA, 
20 mM NaF) supplemented with protease and phosphatase inhibitors cocktail (from Roche) and 1 mM PMSF. 
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Cleared lysates were immunoprecipitated O/N at 4 °C with 2 μ g of mouse anti-V5 antibodies (Invitrogen) fol-
lowed by 1 h of incubation with 30 μ l of agarose-conjugated protein A/G (Santa Cruz Biotechnology). The beads 
were then washed three times in IP buffer and analyzed by immunoblotting.
Western blotting. HeLa cells were lysated in sample buffer at 10000 cells/μ l. All the samples were load in 
a polyacrilamyde gel, transferred onto PVDF membrane and probed with different antibodies: mouse mono-
clonal anti-CFDP1 (1:1000; Sigma-Aldrich); rabbit polyclonal anti-CFDP1 (1:1000, Thermo Scientific); mouse 
monoclonal anti-FLAG (1:1000; Sigma-Aldrich); mouse monoclonal anti-HA (1:1000, Cell Signaling); mouse 
monoclonal anti-c-Myc (1:1000, Clontech); mouse monoclonal anti-V5 (1:1000, Thermo Scientific); rabbit pol-
yclonal anti-HP1α (1:1000, Cell Signaling); rabbit polyclonal anti-histone H2A (1:1000, Millipore); rabbit poly-
clonal anti-p18Hamlet (1:200)48; rabbit polyclonal anti-MEK2 (1:1000, Santa Cruz Biotechnology); rabbit polyclonal 
anti-histone H3 (1:15000, Abcam); rabbit polyclonal anti-H3p (1:5000)49; rabbit polyclonal anti-ISWI (1:5000)50. 
The bands were immunodetected using the Enhanced chemiluminescence (ECL) kit from Thermo Scientific.
Statistical analysis. Data analyses were performed using the GraphPad Prism softwares (GraphPad 
Software, Inc., La Jolla, CA, USA). All results are expressed as mean ± SD values from three independent replicate 
experiments. P value of less than 0.05 (*P < 0.05, compared with the control group) are considered to be statisti-
cally significant by using two-tailed Fisher’s exact test.
Ethical approval and informed consent.  All the methods were carried out in accordance with the 
approved guidelines.
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